OSE Immunotherapeutics SA, Inserm Transfert , and Nantes University announce the signing of a strategic partnership agreement aimed at accelerating the development of innovative projects in the fields of immunotherapy for oncology, inflammation, and autoimmunity.
Health Technology Insights: Kashiv and JAMP Launch PEXEGRA and FILRA Biosimilars in Canada
By combining academic research with industrial expertise, the partnership seeks to transform cutting-edge immunology discoveries into industrial programs capable of delivering breakthrough therapies to patients. This large-scale public–private alliance strengthens long-standing ties with the Immunotherapy Innovation Hub in Nantes and sets the stage for expanding this collaborative model nationwide in the years ahead.
To achieve these objectives, the partners will unite their scientific teams and pool their expertise and know-how to transform innovative projects into programs ready for industrial development. As part of this new partnership, the project identification process led by Inserm Transfert and Nantes University will enable OSE Immunotherapeutics to access the most promising and relevant programs emerging from the research units of Nantes University and Inserm. Selected projects will benefit from financial support and dedicated guidance.
Health Technology Insights: Predictmedix AI Unveils Multi-Vertical Growth Strategy
Pascale Augé, Chairwoman of the Executive Board of Inserm Transfert, said: “This partnership with OSE Immunotherapeutics perfectly illustrates our commitment to supporting excellence in research by fostering synergies between the academic community and French biotech companies. We are very pleased to strengthen long-term collaborations with innovative players firmly rooted in their region, to the benefit of patients. This is a clear example of the vitality of public–private partnerships in the healthcare sector.”
Frédéric Jacquemin, Vice President for Innovation and Partnerships at Nantes University, adds: “Collaborative research at Nantes University is at the heart of our mission. It is built on our academic and hospital strengths, as well as on strong and recognized partnerships. We look forward to further strengthening the complementarity of our expertise and resources within this partnership, in order to foster open research and drive therapeutic innovation for society.”
Nicolas Poirier, Chief Executive Officer of OSE Immunotherapeutics, comments: “We are very pleased to embark on this new collaboration with outstanding teams whose expertise, technologies, and immunotherapy programs are highly complementary to our own. This partnership strengthens our long-standing ties with academic research in Nantes and extends them nationwide, further supporting our ambition to promote immunological innovation throughout France. It also demonstrates our ongoing commitment to bringing innovative immunotherapies to patients with significant unmet medical needs – a shared and central goal of this alliance.”
Health Technology Insights: Xapify Partners to Digitize TSAM Nursing Orientation Framework
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
